AUTHOR CONTRIBUTIONS All the authors participated in the interpretation of the data and critical review of the manuscript and approved this manuscript to be submitted for publication
Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity
For those who want to lose weight without GLP-1 medications (or who want to maintain weight loss after stopping treatment), certain foods that promote GLP-1 in the body may be the answer
SGLT2 inhibitors are preferred in people with HF or at high-risk for HF, whereas GLP-1 receptor agonists are favored for those requiring significant weight loss, ASCVD risk reduction, CKD management, or in whom mitigation of metabolic dysfunction-associated steatotic liver disease (MASLD) or steatohepatitis is a clinical priority [84]
To support our research and testing, we may earn a commission if you sign up or purchase through certain links on this page at no additional cost to you
As a result, your stomach might not be completely empty as expected after fasting for a specific period